Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 20,890 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Terminated Not applicable Interventional Results available

Just-In-Time Adaptive Interventions for Addictive Behaviors

NCT03538652
View directory record Official record
Conditions
Addiction
Interventions
Formative Interviews (not an intervention), Cognitive-behavioral therapy (CBT), Acceptance and commitment therapy (ACT), No intervention
Other · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 23, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

NCT01002547
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
pioglitazone-placebo, pioglitazone, Vitamin E, Vitamin E-placebo
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 23, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

Interoceptive Exposure for Adolescents With Low Weight Eating Disorders

NCT05763849
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Interoceptive Exposure Treatment (IE), Family-Based Treatment (FBT)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 23, 2026, 8:23 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Collecting Data on Retinal Blood Blood Flow and Blood Vessel Shape/Appearance Using an Investigational Device, XyCAM CRE, and to Then Compare Those Images With Images Collected From a Patient's Routine Clinical Examination.

NCT07641738
View directory record Official record
Conditions
Microvascular Disease, Retinal Disease
Interventions
XyCAM CRE Imaging
Device
Lead sponsor
Stuart Terry Eye Associates
Other
Eligibility
21 Years to 100 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

NCT01325558
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
Interventions
ALT-836 in combination with gemcitabine
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 23, 2026, 8:23 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

NCT04656652
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
DS-1062a, Docetaxel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Chandler, Arizona • Anaheim, California • Glendale, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional Results available

Rituxan in Churg Strauss Syndrome With Renal Involvement

NCT00424749
View directory record Official record
Conditions
Churg-Strauss Syndrome
Interventions
Rituximab, Prednisone
Drug
Lead sponsor
Fernando Fervenza
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 23, 2026, 8:23 AM EDT
Not listed Phase 4 Interventional

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 23, 2026, 8:23 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement for Premature Ovarian Insufficiency

NCT02922348
View directory record Official record
Conditions
Primary Ovarian Insufficiency
Interventions
Hormone Replacement Therapy, Combined Oral Contraceptives
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 23, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

Use of the Neurolyser XR for the Treatment of Low Back Pain Related to Sacroiliitis

NCT06053255
View directory record Official record
Conditions
Sacroiliitis
Interventions
High-intensity focused ultrasound for Sacroiliitis using the Neurolyser XR
Device
Lead sponsor
FUSMobile Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 23, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 23, 2026, 8:23 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

NCT05313243
View directory record Official record
Conditions
T-Cell Lymphoma
Interventions
Brentuximab vedotin, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy

NCT01338025
View directory record Official record
Conditions
HIV Disease
Interventions
HAART regimen, 3TC or FTC monotherapy
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
8 Years to 24 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 23, 2026, 8:23 AM EDT
Recruiting No phase listed Observational

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

NCT07390617
View directory record Official record
Conditions
Neuropathy, Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Interventions
Non-therapeutic Nerve Conduction Studies, Non-therapeutic assessment of patient-reported neuropathy
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 8:23 AM EDT
Recruiting No phase listed Observational

Pediatric Radiation Therapy Registry

NCT07129317
View directory record Official record
Conditions
Sarcoma, Pediatric Brain Tumors
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
0 Years to 26 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 23, 2026, 8:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Feasibility of a Mental-Health Intervention Based on Contemplative Sleep Practices

NCT07217340
View directory record Official record
Conditions
Anxiety
Interventions
Dream Yoga Inspired Intervention, Sleep Health Enhancement program
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Evanston, Illinois • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 23, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pictorial Warning Labels & Memory for Relative & Absolute Cigarette Health-risk Information Over Time in Adult Smokers

NCT03499340
View directory record Official record
Conditions
Smoking Cessation, Smoking, Cigarette
Interventions
text-only PWL, low arousal graphic PWL, high arousal graphic PWL, absolute risk, relative risk
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
19 Years to 64 Years
Enrollment
3,213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 23, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema

NCT02348918
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Luminate 1.0mg, Luminate 2.0mg, Luminate 3.0mg, Avastin, Luminate 0.5mg
Drug
Lead sponsor
Allegro Ophthalmics, LLC
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
17
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 23, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Results available

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

NCT02936752
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Entinostat, Pembrolizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
19
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 23, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Neurofeedback Impact on Veterans With mTBI

NCT04195685
View directory record Official record
Conditions
Concussion, mTBI, Post-Concussive Symptoms, Chronic Headache, Chronic Insomnia, Chronic Attention Disorder
Interventions
Neurofeedback (NFB)
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 23, 2026, 8:23 AM EDT
Completed Phase 4 Interventional

Mask Ventilation Before and After Neuromuscular Blockade

NCT02237443
View directory record Official record
Conditions
Anesthesia
Interventions
Rocuronium, Vecuronium Bromide, Succinylcholine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 90 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 23, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Use of Low Level Laser Therapy to Reduce Acne

NCT01276535
View directory record Official record
Conditions
Acne
Interventions
Erchonia MLS + Erchonia THL
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 23, 2026, 8:23 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Treatment of Breast Lift/Reduction Scars

NCT05123508
View directory record Official record
Conditions
Scars
Interventions
2940nm and BBL treatment, Non-treatment side (Control)
Device · Other
Lead sponsor
Sciton
Industry
Eligibility
25 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Greenwood Village, Colorado • Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Oct 23, 2026, 8:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

NCT07488676
View directory record Official record
Conditions
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions
ASP546C
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 8:23 AM EDT